Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& fda max

: 10 mg/d

or Withdrawn 2024

Use the filters below to narrow your results.

Aduhelm (1) · Dayvigo (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · Dual orexin receptor antagonist (DORA) (1)

Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1)

Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1)

5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

5 mg, 10 mg tablets (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

IV infusion every 4 weeks (1) · Oral (1)

PET Aβ reduction over months (1) · ~30 min (1)

Withdrawn (1) · ~7-8 hours (1)

~17-19 hours (longer than daridorexant) (1) · ~25 days (1)

100% (IV) (1) · ~44% (1)

Discontinued/withdrawn (1) · Limited data; avoid (1)

Rx, Schedule IV (US) (1) · Withdrawn from US market January 2024 (1)

Showing below up to 2 results in range #1 to #2.

A

Aducanumab

L

Lemborexant

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"